Clinical trials are run on software from another era.
Sponsors pay for platforms that still require CRAs to compare paper source documents by hand, surface adverse events after the fact, and stitch together data from disconnected vendors. And at the sites running those trials, coordinators still lose days before every monitoring visit — pulling binders, chasing signatures, and hoping nothing surfaces in the findings letter.
wrldOS unifies clinical trial execution.
wrldOS is built to end fragmented clinical trial execution: CTMS, EDC, eTMF, IRT, monitoring, SDV, safety, queries, deviations, documents, audit trail, and agents in one operating system, each screen reading the same record.
Deadlines first, not after the fact.
Serious adverse events are held against their reporting deadlines from the moment they are recorded. Enrollment is held against each site's allocation, with the evidence beside it. Protocol deviations surface in the queue for a person to decide.
Incumbents report after the fact. wrldOS puts the deadline and the evidence in front of you first.Unified, not fragmented.
Command Center consolidates the study's signals — adverse events, proposals, deviations, signatures, queries, visits — into one pane, ordered by consequence. The data you need to run a trial stops living in separate dashboards and inboxes.
Legacy platforms store and manage trial records. wrldOS moves trial execution forward.Agents inside the system, not bolted on.
wrldOS agents operate inside the trial OS — reading signals, identifying risk, drafting next actions, routing work for human review, and preserving the evidence trail. Every proposal carries its evidence, the record version it was made against, and the decision a named person took on it.
Agents in wrldOS are part of the architecture: every proposal is evidence-linked, and a person decides.Six screens. One record. Open it.
wrldOS opens without an account: anyone can read what it holds. Signing in is asked only at the moment you act — approve, dismiss, verify, sign — and every action is recorded in your name, with your role, the time and the reason.
What needs you today across the study, ordered by consequence, then deadline. Proposals open into their evidence and your decision.
One site's next visit: each source document beside its form, every verification mark attributable, findings, and the visit report as it drafts.
The protocol's versions side by side: what each amendment changed, which sites have acknowledged it, which subjects still hold an earlier consent, and the decisions it needs.
Adverse events against their reporting deadlines, deviations with root cause and corrective action, queries ageing at sites, each with its evidence.
Essential documents by version: what is current, what awaits review or signature, what expires, and who signed which version.
Every event in order: who did what, when, under which role, with the value before and after, and what each signature meant.
Three forces changed what this system can be.
Clinical trial infrastructure built this way wasn't possible five years ago. Three things changed.
Regulators have moved to risk-based trials.
wrldOS is built for where the rules now are. ICH E6(R3) Good Clinical Practice — adopted at Step 4 in January 2025, with the FDA's final guidance following in September 2025 — embraces risk-based quality management and innovation in trial design, conduct and technology. wrldOS keeps every agent proposal evidence-linked, audit-trailed and routed to a person before any regulated decision is finalized.
ICH E6(R3) GCP — Step 4, Jan 2025 · FDA final guidance, Sept 2025Trial budgets are now runway.
Sponsors that treated trial software as discretionary now treat it as material to runway. Projected savings of $700K–$1.9M per trial extend runway by months that matter to whether the program reaches its next milestone.
Savings range: wrldOS internal modelThe building blocks are commodity.
Large language models, multi-engine OCR and anomaly detection are available components now. What needed a specialized team to assemble in 2020 is deployable by a small one.
Built by Kelechi Owunwanne — a Clinical Research Associate and operator-founder who spent years across global, mid-size, and specialty CROs. He saw the same structural patterns at every scale, and built what replaces them.
That range matters. Site initiation visits, monitoring visits, close-outs — across multiple operating models, on CTMS, EDC, eTMF, IRT, and safety platforms from every major vendor.
Kelechi on LinkedIn →